Analysis of Proteomic Biomarkers for Acute Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Non-Small Cell Lung Cancer (NSCLC) Patients

被引：0
|
作者：
Nyberg, Fredrik [1 ,2 ]
Ogiwara, Atsushi [3 ,4 ]
Harbron, Chris G. [5 ]
Kawakami, Takao [3 ,4 ,6 ]
Komatsu, Yasuhiko [3 ,4 ]
Nishimura, Toshihide [3 ,4 ,6 ]
Marko-Varga, Gyorgy [7 ]
机构：
[1] AstraZeneca R&D, Epidemiol, Molndal, Sweden
[2] Karolinska Inst, Inst Env Med, Stockholm, Sweden
[3] Med ProteoScope Co Ltd, R&D Div, Tokyo, Japan
[4] Yokohama City Uni, Adv Med Res Ctr, Yokohama, Kanagawa, Japan
[5] AstraZeneca R&D, Discovery Stat, Alderley Pk, Cheshire, England
[6] Tokyo Med Uni, Dep Surg 1, Tokyo, Japan
[7] Lund Uni, Div Clin Prot Sci & Imaging, Biomed Ctr, Lund, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
262
引用
收藏
页码：S112 / S113
页数：2
相关论文
共 50 条
  • [1] Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients
    Nyberg, Fredrik
    Ogiwara, Atsushi
    Harbron, Chris G.
    Kawakami, Takao
    Nagasaka, Keiko
    Takami, Sachiko
    Wada, Kazuya
    Tu, Hsiao-Kun
    Otsuji, Makiko
    Kyono, Yutaka
    Dobashi, Tae
    Komatsu, Yasuhiko
    Kihara, Makoto
    Akimoto, Shingo
    Peers, Ian S.
    South, Marie C.
    Higenbottam, Tim
    Fukuoka, Masahiro
    Nakata, Koichiro
    Ohe, Yuichiro
    Kudoh, Shoji
    Clausen, Ib Groth
    Nishimura, Toshihide
    Marko-Varga, Gyorgy
    Kato, Harubumi
    PLOS ONE, 2011, 6 (07):
  • [2] Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Patients with Non-Small Cell Lung Cancer (NSCLC): Genome-Wide Analysis of Genetic Data
    Nyberg, Fredrik
    Barratt, Bryan
    Nakamura, Yusuke
    Kamatani, Naoyuki
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S25 - S26
  • [3] Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - A retrospective analysis: JMTO LC03-02
    Nakagawa M.
    Nishimura T.
    Teramukai S.
    Tada H.
    Tanaka F.
    Yanagihara K.
    Furuse K.
    Wada H.
    Fukushima M.
    BMC Research Notes, 2 (1)
  • [4] Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group.
    Hotta, K
    Harita, S
    Bessho, A
    Yonei, T
    Gemba, K
    Aoe, K
    Tabata, M
    Kiura, K
    Ueoka, H
    Tanimoto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 632S - 632S
  • [5] Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data
    Nyberg, Fredrik
    Barratt, Bryan J.
    Mushiroda, Taisei
    Takahashi, Atsushi
    Jawaid, Ansar
    Hada, Shuji
    Umemura, Takaaki
    Fukuoka, Masahiro
    Nakata, Koichiro
    Ohe, Yuichiro
    Kato, Harubumi
    Kudoh, Shoji
    March, Ruth
    Nakamura, Yusuke
    Kamatani, Naoyuki
    PHARMACOGENOMICS, 2011, 12 (07) : 965 - 975
  • [6] NESTED CASE CONTROL STUDY OF PROTEOMIC BIOMARKERS FOR INTERSTITIAL LUNG DISEASE IN JAPANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB
    Katakami, N.
    Atagi, S.
    Yoshioka, H.
    Fukuoka, M.
    Ogiwara, A.
    Imai, M.
    Ueda, M.
    Matsui, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 91 - 92
  • [7] NESTED CASE CONTROL STUDY OF PROTEOMIC BIOMARKERS FOR INTERSTITIAL LUNG DISEASE IN JAPANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB
    Katakami, Nobuyuki
    Atagi, Shinji
    Yoshioka, Hiroshige
    Fukuoka, Masahiro
    Ogiwara, Atsushi
    Imai, Masato
    Ueda, Masamichi
    Matsui, Shigeyuki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S458 - S458
  • [8] Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study.
    Nakaga, M
    Teramukai, S
    Tada, H
    Furuse, K
    Tanaka, F
    Mio, T
    Mishima, M
    Wada, H
    Fukushima, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 667S - 667S
  • [9] Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer
    Okami, Jiro
    Taniguchi, Kazuya
    Higashiyama, Masahiko
    Maeda, Jun
    Oda, Kazuyuki
    Orita, Naoki
    Koizumi, Kyoko
    Kodama, Ken
    Kato, Kikuya
    ONCOLOGY, 2007, 72 (3-4) : 234 - 242
  • [10] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
12345